Peginesatide in patients with anemia undergoing hemodialysis

New England Journal of Medicine

Volumn 368, Issue 4, 2013, Pages 307-319

  Fishbane, Steven ^a   Schiller, Brigitte ^b   Locatelli, Francesco ^d   Covic, Adrian C ^e   Provenzano, Robert ^f   Wiecek, Andrzej ^h   Levin, Nathan W ⁱ   Kaplan, Mark ^j   Macdougall, Iain C ^k   Francisco, Carol ^c   Mayo, Martha R ^c   Polu, Krishna R ^c   Duliege, Anne Marie ^c   Besarab, Anatole ^g  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b CA   (United States)

^c AFFYMAX RESEARCH INSTITUTE   (United States)

^d A MANZONI HOSPITAL   (Italy)

^e Clinical Hospital of Pneumology   (Romania)

^f HENRY FORD HEALTH SYSTEM   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MEDICAL UNIVERSITY OF SILESIA   (Poland)

ⁱ RENAL RESEARCH INSTITUTE   (United States)

^j Nephrology Associates   (United States)

^k KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN;

ACUTE HEART INFARCTION; ADULT; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; CARDIOVASCULAR RISK; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONVULSION; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERVOLEMIA; IMMUNOGENICITY; INFUSION RELATED REACTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SUDDEN DEATH; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

EID: 84872782188     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1203165     Document Type: Article

References (17)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8.
2. Winearls CG. Historical review on the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dial Transplant 1995;10:Suppl 2:3-9.
3. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990;300:573-8.
4. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
5. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
6. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
7. 2010 Annual report of the Dialysis Outcomes and Practice Patterns Study: hemodialysis data 1999-2008. Ann Arbor, MI: Arbor Research Collaborative for Health, 2010 (http://www.dopps.org/annualreport).
8. Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-40.
9. Woodburn KW, Holmes CP, Wilson SD, et al. Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica 2012;42:660-70.
10. Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007;35:1201-8.
11. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietin agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006;108:1830-4.
12. Macdougall IC, Wiecek A, Tucker B, et al. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 2011;6:2579-86.
13. Besarab A, Zeig SN, Martin ER, et al. An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients. BMC Nephrol 2012;13:95.
14. Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32.
15. Postorino M, Marino C, Tripepi G, Zoccali C. Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant 2007;22:1377-82.
16. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
17. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009;361:1848-55.